What does Shift Bioscience do?

Shift Bioscience is a biotechnology company based in Cambridge, UK, founded in 2017. The company focuses on developing therapies aimed at reversing aging through safe cellular rejuvenation. It targets age-related diseases by reducing cellular age while maintaining cell identity. Shift Bioscience utilizes advanced technologies, including single-cell sequencing and AI-powered virtual cell models, to accelerate research and discovery. The company has developed a proprietary single-cell aging clock and a machine learning platform that allows for in silico experiments. This technology helps identify gene-based interventions that can influence epigenetic age. Shift is advancing an AI-driven pipeline of therapeutic candidates, with initial targets including age-driven hearing loss, liver fibrosis, and systemic sclerosis. The company emphasizes a safety-first approach, focusing on epigenetic modifications and DNA repair mechanisms. Shift Bioscience combines in-house research and development with strategic partnerships to enhance therapy development. It serves the healthcare and biotech research sectors, providing cell simulations and aging biomarker development. The company is supported by investors such as F-Prime Capital.